CJC-1295 + Ipamorelin

Description

CJC-1295 and Ipamorelin represent two distinct classes of growth hormone secretagogue peptides that, when combined, create a synergistic research model for studying the hypothalamic-pituitary growth hormone axis. CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), a 29-amino-acid peptide modified with a Drug Affinity Complex (DAC) that extends its biological half-life from minutes to several days. Ipamorelin is a selective growth hormone-releasing peptide (GHRP) that acts on the ghrelin receptor (GHS-R1a) to stimulate pituitary somatotrophs through a mechanism independent of GHRH signaling.

The pharmacological rationale for combining these two peptides centers on their complementary receptor targets. CJC-1295 binds to the GHRH receptor on pituitary somatotroph cells, initiating a cAMP-dependent signaling cascade that primes these cells for growth hormone (GH) synthesis and release. Ipamorelin acts on the distinct GHS-R1a receptor, amplifying the GH release signal through a separate intracellular pathway involving phospholipase C and protein kinase C. Research data indicates that co-administration produces a significantly greater GH pulse amplitude than either peptide alone, a phenomenon well-documented in secretagogue literature as synergistic potentiation.

A critical advantage of Ipamorelin over earlier-generation GHRPs such as GHRP-6 and GHRP-2 is its selectivity profile. In preclinical studies, Ipamorelin has demonstrated minimal effects on cortisol, prolactin, and aldosterone levels at GH-stimulating concentrations, making it a cleaner research tool for isolating GH-specific effects. This selectivity reduces confounding variables in experimental designs focused on the somatotropic axis. When paired with the sustained GHRH-receptor activation provided by CJC-1295, the combination enables researchers to study prolonged, pulsatile GH release patterns that more closely mimic physiological secretion dynamics.

Body composition studies in animal models have shown that sustained elevation of GH through this dual-pathway approach is associated with measurable changes in lean mass accretion and adipose tissue metabolism. The pulsatile nature of GH release induced by this combination, rather than continuous elevation, has been identified as a key factor in maintaining receptor sensitivity and avoiding desensitization artifacts that can complicate long-term research protocols. Additionally, IGF-1 levels, the primary mediator of many GH effects, show dose-dependent increases in response to combined CJC-1295 and Ipamorelin treatment in rodent models.

This product is supplied as a co-lyophilized powder containing 5mg of CJC-1295 and 5mg of Ipamorelin in a single vial. Both components exceed 98% purity as verified by independent HPLC analysis. Reconstitute with bacteriostatic water and use according to your institutional research protocols.

Composition

• Component 1: CJC-1295 (Modified GRF 1-29)
• CJC-1295 Molecular Formula: C152H252N44O42
• CJC-1295 Molecular Weight: 3367.97 g/mol
• Component 2: Ipamorelin
• Ipamorelin Molecular Formula: C38H49N9O5
• Ipamorelin Molecular Weight: 711.85 g/mol
• Purity: >98% each component (HPLC)
• Appearance: White lyophilized powder
• Quantity: 5mg + 5mg per vial

Storage

• Store lyophilized peptide at -20C for long-term storage (up to 24 months).
• For short-term storage (up to 4 weeks), refrigerate at 2-8C.
• After reconstitution, store at 2-8C and use within 21 days.
• Avoid repeated freeze-thaw cycles.
• Protect from light and moisture at all times.

Certificate of Analysis

Every batch of CJC-1295 + Ipamorelin sold by Pepspan undergoes comprehensive dual-component third-party testing. Our Certificate of Analysis (COA) includes individual HPLC purity analysis for both CJC-1295 and Ipamorelin, mass spectrometry confirmation of each peptide, endotoxin testing, and sterility verification. COA documentation is available upon request for any batch number. All testing is performed by independent European laboratories.

Current Batch: Pending first shipment

Every batch of CJC-1295 + Ipamorelin sold by Pepspan is independently tested by Janoshik Analytical (Prague, Czech Republic). HPLC purity analysis, mass spectrometry, and amino acid sequencing are performed for each shipment. Reports are batch-specific — not generic.

Research Disclaimer

This product is intended for laboratory research use only. It is not a drug, food, cosmetic, or dietary supplement. CJC-1295 and Ipamorelin are not approved for human or veterinary use by any regulatory agency. They must not be administered to humans or animals outside of approved clinical trials. By purchasing this product, you confirm that you are a qualified researcher and that this product will be used exclusively for legitimate scientific research purposes. Pepspan assumes no liability for any misuse of this product. All handling must comply with local regulations and institutional safety protocols.